Skip to content
FDA Import Alert · 66-40

Huons Co., Ltd. · Jecheon, KOREA (THE REPUBLIC OF)

Listed 2026-04-03 · 15 product codes · Source: FDA Import Alert 66-40 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Huons Co., Ltd.

10 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2026-06-23 ~ 2026-11-12

Areas cited

Aseptic processing and sterility assuranceLaboratory and QC controlsDeviation, CAPA, and investigationDocumentation and records

Published inspection documents

Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm failed to open adequate investigations into out-of-specification (OOS) results. For example, (b)(4) batch (b)(4) failed initial testing due to unknown impurities. Your firm opened an out-of-specification investigation that included performing hypothesis testing for contaminated glassware. To simulate your hypothesis, your firm prepared a second sample using glassware marked for disposal to mimic the original failed sample. This second sample met acceptance criteria. Your firm still used the passing hypothesis test results as justification to invalidate the original test result. You also failed to adequately investigate other out-of-specification results, including the endotoxin failure discussed under the first violation in this warning letter. In response you indicated that your firm is conducting a retrospective assessment of all OOS investigations for all U.S. drug products on the market, but you did not provide a specific timeline for completion. Your response is also inadequate because it fails to sufficiently address the need for improved quality unit (QU) oversight of investigations. In addition, the data integrity issues at your firm significantly compromise your QU’s ability to perform its obligation to assess laboratory data and evaluate OOS investigations. For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of- Specification (OOS) Test Results for Pharmaceutical Production at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. In response to this letter provide: A retrospective, independent review of all invalidated OOS (including in-process and release/stability testing) results for US products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error. o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation. o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation and any manufacturing operation improvements. A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to: o A determination of whether procedures used by your firm are robust and appropriate. o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision. o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. 2026-06-23 US FDA 4 findingsDeviation, CAPA, and investigation · Aseptic processing and sterility assurance and 1 more View the regulator's official source

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Huons Co., Ltd. — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.